Head-to-head evidence
Naptumomab estafenatox vs TUB-030
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: 5T4 (trophoblast glycoprotein, TPBG) · full Non-Small Cell Lung Cancer pipeline
Naptumomab estafenatox
Developed by NeoTX Therapeutics Ltd.
NCT04880863 · Phase 2 · completed
The study was open-label, non-randomized, and had no control group, with 38 participants receiving naptumomab estafenatox in combination with docetaxel and obinutuzumab. Its imaging-based objective response endpoint was reported, but without a comparator there was no formal treatment comparison, so the findings provide limited evidence for naptumomab estafenatox.
Next expected readout: March 2027 · NCT03983954 (registry estimate)
TUB-030
Developed by Tubulis GmbH
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT06657222 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Naptumomab estafenatox's landscape · TUB-030's landscape